FDA Rejects Verily’s Smartwatch for Parkinson’s Assessment

The U.S. Food and Drug Administration (FDA) has rejected an application from Verily Life Sciences that sought to add a Parkinson’s disease symptom assessment tool to the company’s clinical research-focused smartwatch.

In its response letter, the FDA said there was not enough evidence that the criteria evaluated in the assessment were meaningful for patients’ lives.